Here are four things to know.
1. The clinical study will include 40 subjects who are already scheduled for TKR surgery. Each subject will be randomly assigned to receive an active or placebo device.
2. Study enrollment has begun, and the study is set to finish December 2018.
3. The study is being conducted at the New Mazloum Hospital in Tripoli, Lebanon. BioElectronic’s distributor in Lebanon, Dr. Omar Tabbouche, is managing the study and introducing BioElectronics’ devices into the Lebanese marketplace.
4. The study will help RecoveryRx gain regulatory clearance, according to Ian Rawe, PhD, director of clinical research at BioElectronics.
Here is more information on the study.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. David Dalury of Towson Orthopaedic Associates
Dr. Melissa Kounine joins Washington Orthopaedic Center
50+ female orthopedic surgeons in the US
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
